<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32468476</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0065-2598</ISSN><JournalIssue CitedMedium="Print"><Volume>1195</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Advances in experimental medicine and biology</Title><ISOAbbreviation>Adv Exp Med Biol</ISOAbbreviation></Journal><ArticleTitle>Amyotrophic Lateral Sclerosis: Current Status in Diagnostic Biomarkers.</ArticleTitle><Pagination><StartPage>179</StartPage><EndPage>187</EndPage><MedlinePgn>179-187</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/978-3-030-32633-3_26</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a rare, neurodegenerative disease that affects the human motor system. ALS is a highly heterogeneous disease, depending on several causative factors. The heterogeneity of the disease is also reflected in the variation of the symptoms in ALS patients. The worldwide annual incidence of ALS is about 2.08 per 100,000 with uniform rates in Caucasian populations and lower rates in African, Asian, and Hispanic populations, while the number of individuals with ALS is expected to grow significantly between 2015 and 2040 with an estimated increase of 69% (Chio et al. 2013a; Arthur et al. 2016).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kadena</LastName><ForeName>Katerina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Informatics, Ionian University, Corfu, Greece. katerina.kadena@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vlamos</LastName><ForeName>Panayiotis</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Informatics, Ionian University, Corfu, Greece. vlamos@ionio.gr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Adv Exp Med Biol</MedlineTA><NlmUniqueID>0121103</NlmUniqueID><ISSNLinking>0065-2598</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044469" MajorTopicYN="N">Racial Groups</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32468476</ArticleId><ArticleId IdType="doi">10.1007/978-3-030-32633-3_26</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arthur KC et al (2016) Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat Commun 7:12408</Citation><ArticleIdList><ArticleId IdType="pubmed">27510634</ArticleId><ArticleId IdType="pmc">4987527</ArticleId><ArticleId IdType="doi">10.1038/ncomms12408</ArticleId></ArticleIdList></Reference><Reference><Citation>Barschke P et al (2017) Proteomic studies in the discovery of cerebrospinal fluid biomarkers for amyotrophic lateral sclerosis. Expert Rev Proteomics 14(9):769&#x2013;777</Citation><ArticleIdList><ArticleId IdType="pubmed">28799854</ArticleId><ArticleId IdType="doi">10.1080/14789450.2017.1365602</ArticleId><ArticleId IdType="pmc">28799854</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M et al (2016) ALS biomarkers for therapy development: state of the field and future directions. Muscle Nerve 53(2):169&#x2013;182</Citation><ArticleIdList><ArticleId IdType="pubmed">26574709</ArticleId><ArticleId IdType="doi">10.1002/mus.24979</ArticleId><ArticleId IdType="pmc">26574709</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H et al (2016a) Further development of biomarkers in amyotrophic lateral sclerosis. Expert Rev Mol Diagn 16(8):853&#x2013;868</Citation><ArticleIdList><ArticleId IdType="pubmed">27275785</ArticleId><ArticleId IdType="doi">10.1080/14737159.2016.1199277</ArticleId><ArticleId IdType="pmc">27275785</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H et al (2016b) Biomarkers in amyotrophic lateral sclerosis: combining metabolomic and clinical parameters to define disease progression. Eur J Neurol 23(2):346&#x2013;353</Citation><ArticleIdList><ArticleId IdType="pubmed">26508442</ArticleId><ArticleId IdType="doi">10.1111/ene.12851</ArticleId><ArticleId IdType="pmc">26508442</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H et al (2016c) Metabolomics in amyotrophic lateral sclerosis: how far can it take us? Eur J Neurol 23(3):447&#x2013;454</Citation><ArticleIdList><ArticleId IdType="pubmed">26822316</ArticleId><ArticleId IdType="doi">10.1111/ene.12956</ArticleId><ArticleId IdType="pmc">26822316</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J et&#xa0;al (2006) Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 66(6):852&#x2013;856</Citation><ArticleIdList><ArticleId IdType="pubmed">16567701</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000203120.85850.54</ArticleId><ArticleId IdType="pmc">16567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos-Melo D et al (2013) Altered microRNA expression profile in Amyotrophic Lateral Sclerosis: a role in the regulation of NFL mRNA levels. Mol Brain 6:26</Citation><ArticleIdList><ArticleId IdType="pubmed">23705811</ArticleId><ArticleId IdType="pmc">3668997</ArticleId><ArticleId IdType="doi">10.1186/1756-6606-6-26</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Shang HF (2015) New developments and future opportunities in biomarkers for amyotrophic lateral sclerosis. Transl Neurodegener 4:17</Citation><ArticleIdList><ArticleId IdType="pubmed">26425343</ArticleId><ArticleId IdType="pmc">4589120</ArticleId><ArticleId IdType="doi">10.1186/s40035-015-0040-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HJ et al (2010) Characterization of the properties of a novel mutation in VAPB in familial amyotrophic lateral sclerosis. J Biol Chem 285(51):40266&#x2013;40281</Citation><ArticleIdList><ArticleId IdType="pubmed">20940299</ArticleId><ArticleId IdType="pmc">3001007</ArticleId><ArticleId IdType="doi">10.1074/jbc.M110.161398</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X et al (2016a) Assessment of a multiple biomarker panel for diagnosis of amyotrophic lateral sclerosis. BMC Neurol 16:173</Citation><ArticleIdList><ArticleId IdType="pubmed">27634542</ArticleId><ArticleId IdType="pmc">5024522</ArticleId><ArticleId IdType="doi">10.1186/s12883-016-0689-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y et al (2016b) Proteomic analysis of cerebrospinal fluid in amyotrophic lateral sclerosis. Exp Ther Med 11(6):2095&#x2013;2106</Citation><ArticleIdList><ArticleId IdType="pubmed">27284291</ArticleId><ArticleId IdType="pmc">4887813</ArticleId><ArticleId IdType="doi">10.3892/etm.2016.3210</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A et al (2013a) Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41(2):118&#x2013;130</Citation><ArticleIdList><ArticleId IdType="pubmed">23860588</ArticleId><ArticleId IdType="pmc">4049265</ArticleId><ArticleId IdType="doi">10.1159/000351153</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A et al (2013b) UNC13A influences survival in Italian amyotrophic lateral sclerosis patients: a population-based study. Neurobiol Aging 34(1):357 e1&#x2013;357 e5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.07.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Cloutier F et al (2015) MicroRNAs as potential circulating biomarkers for amyotrophic lateral sclerosis. J Mol Neurosci 56(1):102&#x2013;112</Citation><ArticleIdList><ArticleId IdType="pubmed">25433762</ArticleId><ArticleId IdType="doi">10.1007/s12031-014-0471-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H, Gao K, Jankovic J (2014) The role of FUS gene variants in neurodegenerative diseases. Nat Rev Neurol 10(6):337&#x2013;348</Citation><ArticleIdList><ArticleId IdType="pubmed">24840975</ArticleId><ArticleId IdType="doi">10.1038/nrneurol.2014.78</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G et al (2015) Muscle expression of SOD1(G93A) modulates microRNA and mRNA transcription pattern associated with the myelination process in the spinal cord of transgenic mice. Front Cell Neurosci 9:463</Citation><ArticleIdList><ArticleId IdType="pubmed">26648847</ArticleId><ArticleId IdType="pmc">4664730</ArticleId><ArticleId IdType="doi">10.3389/fncel.2015.00463</ArticleId></ArticleIdList></Reference><Reference><Citation>Grolez G et al (2016) The value of magnetic resonance imaging as a biomarker for amyotrophic lateral sclerosis: a systematic review. BMC Neurol 16(1):155</Citation><ArticleIdList><ArticleId IdType="pubmed">27567641</ArticleId><ArticleId IdType="pmc">5002331</ArticleId><ArticleId IdType="doi">10.1186/s12883-016-0672-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha M, Kim VN (2014) Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 15(8):509&#x2013;524</Citation><ArticleIdList><ArticleId IdType="pubmed">25027649</ArticleId><ArticleId IdType="doi">10.1038/nrm3838</ArticleId><ArticleId IdType="pmc">25027649</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawley ZCE et al (2017) MotomiRs: miRNAs in motor neuron function and disease. Front Mol Neurosci 10:127</Citation><ArticleIdList><ArticleId IdType="pubmed">28522960</ArticleId><ArticleId IdType="pmc">5415563</ArticleId><ArticleId IdType="doi">10.3389/fnmol.2017.00127</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishtiaq M et al (2014) Analysis of novel NEFL mRNA targeting microRNAs in amyotrophic lateral sclerosis. PLoS One 9(1):e85653</Citation><ArticleIdList><ArticleId IdType="pubmed">24454911</ArticleId><ArticleId IdType="pmc">3893244</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0085653</ArticleId></ArticleIdList></Reference><Reference><Citation>Junttila A et al (2016) Cerebrospinal fluid TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis patients with and without the C9ORF72 Hexanucleotide expansion. Dement Geriatr Cogn Dis Extra 6(1):142&#x2013;149</Citation><ArticleIdList><ArticleId IdType="pubmed">27195002</ArticleId><ArticleId IdType="pmc">4868946</ArticleId><ArticleId IdType="doi">10.1159/000444788</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamelgarn M et al (2016) Proteomic analysis of FUS interacting proteins provides insights into FUS function and its role in ALS. Biochim Biophys Acta 1862(10):2004&#x2013;2014</Citation><ArticleIdList><ArticleId IdType="pubmed">27460707</ArticleId><ArticleId IdType="pmc">5055831</ArticleId><ArticleId IdType="doi">10.1016/j.bbadis.2016.07.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasai T et al (2009) Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol 117(1):55&#x2013;62</Citation><ArticleIdList><ArticleId IdType="pubmed">18989684</ArticleId><ArticleId IdType="doi">10.1007/s00401-008-0456-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Lee VM, Trojanowski JQ (2011) Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci 13(1):38&#x2013;50</Citation><ArticleIdList><ArticleId IdType="pubmed">22127299</ArticleId><ArticleId IdType="pmc">3285250</ArticleId><ArticleId IdType="doi">10.1038/nrn3121</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazon M et al (2018) Imaging biomarkers for the diagnosis and prognosis of neurodegenerative diseases. The example of amyotrophic lateral sclerosis. Front Neurosci 12:784</Citation><ArticleIdList><ArticleId IdType="pubmed">30410433</ArticleId><ArticleId IdType="pmc">6209630</ArticleId><ArticleId IdType="doi">10.3389/fnins.2018.00784</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, McGeer EG (2002) Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 26(4):459&#x2013;470</Citation><ArticleIdList><ArticleId IdType="pubmed">12362410</ArticleId><ArticleId IdType="doi">10.1002/mus.10191</ArticleId></ArticleIdList></Reference><Reference><Citation>Munch C, Bertolotti A (2010) Exposure of hydrophobic surfaces initiates aggregation of diverse ALS-causing superoxide dismutase-1 mutants. J Mol Biol 399(3):512&#x2013;525</Citation><ArticleIdList><ArticleId IdType="pubmed">20399791</ArticleId><ArticleId IdType="pmc">2927901</ArticleId><ArticleId IdType="doi">10.1016/j.jmb.2010.04.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura AL et al (2004) A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet 75(5):822&#x2013;831</Citation><ArticleIdList><ArticleId IdType="pubmed">15372378</ArticleId><ArticleId IdType="pmc">1182111</ArticleId><ArticleId IdType="doi">10.1086/425287</ArticleId></ArticleIdList></Reference><Reference><Citation>Parisi C et al (2013) Dysregulated microRNAs in amyotrophic lateral sclerosis microglia modulate genes linked to neuroinflammation. Cell Death Dis 4:e959</Citation><ArticleIdList><ArticleId IdType="pubmed">24336079</ArticleId><ArticleId IdType="pmc">3877562</ArticleId><ArticleId IdType="doi">10.1038/cddis.2013.491</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganathan S et al (2005) Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem 95(5):1461&#x2013;1471</Citation><ArticleIdList><ArticleId IdType="pubmed">16313519</ArticleId><ArticleId IdType="pmc">1540444</ArticleId><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03478.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM (2016) How neuroinflammation contributes to neurodegeneration. Science 353(6301):777&#x2013;783</Citation><ArticleIdList><ArticleId IdType="pubmed">27540165</ArticleId><ArticleId IdType="doi">10.1126/science.aag2590</ArticleId><ArticleId IdType="pmc">27540165</ArticleId></ArticleIdList></Reference><Reference><Citation>Recabarren-Leiva D, Alarcon M (2018) New insights into the gene expression associated to amyotrophic lateral sclerosis. Life Sci 193:110&#x2013;123</Citation><ArticleIdList><ArticleId IdType="pubmed">29241710</ArticleId><ArticleId IdType="doi">10.1016/j.lfs.2017.12.016</ArticleId><ArticleId IdType="pmc">29241710</ArticleId></ArticleIdList></Reference><Reference><Citation>Reijn TS et al (2009) CSF neurofilament protein analysis in the differential diagnosis of ALS. J Neurol 256(4):615&#x2013;619</Citation><ArticleIdList><ArticleId IdType="pubmed">19296046</ArticleId><ArticleId IdType="doi">10.1007/s00415-009-0131-z</ArticleId><ArticleId IdType="pmc">19296046</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinchetti P et al (2018) MicroRNA metabolism and dysregulation in amyotrophic lateral sclerosis. Mol Neurobiol 55(3):2617&#x2013;2630</Citation><ArticleIdList><ArticleId IdType="pubmed">28421535</ArticleId><ArticleId IdType="doi">10.1007/s12035-017-0537-z</ArticleId><ArticleId IdType="pmc">28421535</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringholz GM et al (2005) Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 65(4):586&#x2013;590</Citation><ArticleIdList><ArticleId IdType="pubmed">16116120</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000172911.39167.b6</ArticleId><ArticleId IdType="pmc">16116120</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD et al (2015) C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. Lancet Neurol 14(3):291&#x2013;301</Citation><ArticleIdList><ArticleId IdType="pubmed">25638642</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(14)70233-9</ArticleId><ArticleId IdType="pmc">25638642</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 364(6435):362</Citation><ArticleIdList><ArticleId IdType="pubmed">8332197</ArticleId><ArticleId IdType="doi">10.1038/364362c0</ArticleId><ArticleId IdType="pmc">8332197</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryberg H, Bowser R (2008) Protein biomarkers for amyotrophic lateral sclerosis. Expert Rev Proteomics 5(2):249&#x2013;262</Citation><ArticleIdList><ArticleId IdType="pubmed">18466055</ArticleId><ArticleId IdType="doi">10.1586/14789450.5.2.249</ArticleId><ArticleId IdType="pmc">18466055</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith BN et al (2013) The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a single founder. Eur J Hum Genet 21(1):102&#x2013;108</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejhg.2012.98</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P et al (2008) TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol 65(11):1481&#x2013;1487</Citation><ArticleIdList><ArticleId IdType="pubmed">19001167</ArticleId><ArticleId IdType="pmc">2690860</ArticleId><ArticleId IdType="doi">10.1001/archneur.65.11.1481</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ et al (2009) Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 10(3):131&#x2013;146</Citation><ArticleIdList><ArticleId IdType="pubmed">19462523</ArticleId><ArticleId IdType="doi">10.1080/17482960802654364</ArticleId><ArticleId IdType="pmc">19462523</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki H et al (2009) ALS-linked P56S-VAPB, an aggregated loss-of-function mutant of VAPB, predisposes motor neurons to ER stress-related death by inducing aggregation of co-expressed wild-type VAPB. J Neurochem 108(4):973&#x2013;985</Citation><ArticleIdList><ArticleId IdType="pubmed">19183264</ArticleId><ArticleId IdType="doi">10.1111/j.1471-4159.2008.05857.x</ArticleId><ArticleId IdType="pmc">19183264</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan L et al (2016) Toward precision medicine in neurological diseases. Ann Transl Med 4(6):104</Citation><ArticleIdList><ArticleId IdType="pubmed">27127757</ArticleId><ArticleId IdType="pmc">4828730</ArticleId><ArticleId IdType="doi">10.21037/atm.2016.03.26</ArticleId></ArticleIdList></Reference><Reference><Citation>Toivonen JM et al (2014) MicroRNA-206: a potential circulating biomarker candidate for amyotrophic lateral sclerosis. PLoS One 9(2):e89065</Citation><ArticleIdList><ArticleId IdType="pubmed">24586506</ArticleId><ArticleId IdType="pmc">3930686</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0089065</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA et al (2009) Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet 41(10):1083&#x2013;1087</Citation><ArticleIdList><ArticleId IdType="pubmed">19734901</ArticleId><ArticleId IdType="pmc">19734901</ArticleId><ArticleId IdType="doi">10.1038/ng.442</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal-Taboada JM et al (2015) UNC13A confers risk for sporadic ALS and influences survival in a Spanish cohort. J Neurol 262(10):2285&#x2013;2292</Citation><ArticleIdList><ArticleId IdType="pubmed">26162714</ArticleId><ArticleId IdType="doi">10.1007/s00415-015-7843-z</ArticleId><ArticleId IdType="pmc">26162714</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu LT, Tsukahara T (2017) C-to-U editing and site-directed RNA editing for the correction of genetic mutations. Biosci Trends 11(3):243&#x2013;253</Citation><ArticleIdList><ArticleId IdType="pubmed">28484188</ArticleId><ArticleId IdType="doi">10.5582/bst.2017.01049</ArticleId><ArticleId IdType="pmc">28484188</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams AH et al (2009) MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science 326(5959):1549&#x2013;1554</Citation><ArticleIdList><ArticleId IdType="pubmed">20007902</ArticleId><ArticleId IdType="pmc">2796560</ArticleId><ArticleId IdType="doi">10.1126/science.1181046</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson ME et al (2010) Cystatin C: a candidate biomarker for amyotrophic lateral sclerosis. PLoS One 5(12):e15133</Citation><ArticleIdList><ArticleId IdType="pubmed">21151566</ArticleId><ArticleId IdType="pmc">3000338</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0015133</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao S et al (2015) Low molecular weight species of TDP-43 generated by abnormal splicing form inclusions in amyotrophic lateral sclerosis and result in motor neuron death. Acta Neuropathol 130(1):49&#x2013;61</Citation><ArticleIdList><ArticleId IdType="pubmed">25788357</ArticleId><ArticleId IdType="pmc">4468798</ArticleId><ArticleId IdType="doi">10.1007/s00401-015-1412-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu ZP et al (2016a) Biomarkers for early diagnostic of mild cognitive impairment in Type-2 diabetes patients: a multicentre, retrospective, nested case-control study. EBioMedicine 5:105&#x2013;113</Citation><ArticleIdList><ArticleId IdType="pubmed">27077117</ArticleId><ArticleId IdType="pmc">4816853</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2016.02.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z et al (2016b) Neurofilaments as biomarkers for amyotrophic lateral sclerosis: a systematic review and meta-analysis. PLoS One 11(10):e0164625</Citation><ArticleIdList><ArticleId IdType="pubmed">27732645</ArticleId><ArticleId IdType="pmc">5061412</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0164625</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F et al (2013) miRNA-9 expression is upregulated in the spinal cord of G93A-SOD1 transgenic mice. Int J Clin Exp Pathol 6(9):1826&#x2013;1838</Citation><ArticleIdList><ArticleId IdType="pubmed">24040447</ArticleId><ArticleId IdType="pmc">3759489</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>